Stock Events

Stock Events

Structure Therapeutics 

$47.34
48
-$0.00-0% 20:00 Today
+$0.00+0%20:04After hours

Statistics

Day High
48.06
Day Low
46.73
52W High
94.9
52W Low
19.5
Volume
253,396
Avg. Volume
743,249
Mkt Cap
3.38B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MayExpected
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-1.14
-0.76
-0.38
0
Expected EPS
-0.22
Actual EPS
0

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-141.2MNet Income

Analyst Ratings

94.50Average Price Target
The highest estimate is 110.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GPCR. It's not an investment recommendation.
Lilly(Eli) &
9
LLY
Amazon
8
AMZN
Microsoft
7
MSFT
NVIDIA
7
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a leader in treating cystic fibrosis, a focus area that overlaps with Structure Therapeutics' GPCR-targeted therapies, making them direct competitors in drug development for similar diseases.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, areas where Structure Therapeutics could potentially compete through its GPCR-focused therapies.
AMGEN
AMGN
Mkt Cap233.78B
Amgen operates in various therapeutic areas, including cardiovascular disease, oncology, and inflammation, competing with Structure Therapeutics in the broad scope of drug development and innovation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, directly competing with Structure Therapeutics in the development of novel therapies targeting GPCRs.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurological diseases, an area where Structure Therapeutics' GPCR-targeted approach could offer competitive therapeutic options.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in areas including immunology and oncology, where Structure Therapeutics' GPCR-focused drug development could present direct competition.
Merck
MRK
Mkt Cap366B
Merck & Co. is a global healthcare company that could compete with Structure Therapeutics in various therapeutic areas through its extensive drug development pipeline.
Pfizer
PFE
Mkt Cap159.36B
Pfizer's broad range of therapeutic areas and significant R&D investment make it a competitor to Structure Therapeutics, especially in GPCR-targeted drug development.
Novartis
NVS
Mkt Cap292.35B
Novartis focuses on a wide range of healthcare areas, including the rapidly evolving field of targeted therapies where Structure Therapeutics operates.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a diverse portfolio in respiratory, cardiovascular, renal, metabolism, and oncology, competing with Structure Therapeutics in the development of novel therapeutics.

About

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Show more...
CEO
Raymond C. Stevens
Employees
281
Country
Cayman Islands
ISIN
US86366E1064

Listings

XNAS
US
GPCR
BOATS
BOATS
GPCR.BOATS

0 Comments

Share your thoughts

FAQ

What is Structure Therapeutics stock price today?▼
The current price of GPCR is $47.34 USD — it has decreased by -0% in the past 24 hours. Watch Structure Therapeutics stock price performance more closely on the chart.
What is Structure Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Structure Therapeutics stocks are traded under the ticker GPCR.
Is Structure Therapeutics stock price growing?▼
GPCR stock has fallen by -0.06% compared to the previous week, the month change is a -4.63% fall, over the last year Structure Therapeutics has showed a +139.57% increase.
What is Structure Therapeutics market cap?▼
Today Structure Therapeutics has the market capitalization of 3.38B
What were Structure Therapeutics earnings last quarter?▼
GPCR earnings for the last quarter are 0 USD per share, whereas the estimation was -0.22 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Structure Therapeutics revenue for the last year?▼
Structure Therapeutics revenue for the last year amounts to 0 USD.
What is Structure Therapeutics net income for the last year?▼
GPCR net income for the last year is -141.2M USD.
How many employees does Structure Therapeutics have?▼
As of September 04, 2026, the company has 281 employees.
In which sector is Structure Therapeutics located?▼
Structure Therapeutics operates in the Health & Wellness sector.
When did Structure Therapeutics complete a stock split?▼
Structure Therapeutics has not had any recent stock splits.
Where is Structure Therapeutics headquartered?▼
Structure Therapeutics is headquartered in SOUTH SAN FRANCISCO, Cayman Islands.